NYXOAH S A Stock Price, News & Analysis

Nyxoah SA (NYXH) received three transparency notifications following changes in shareholdings:

• Jürgen Hambrecht and JH Capital GmbH now hold 1,344,000 voting rights (3.91%) after crossing the 3% threshold on September 5, 2024.
• BlackRock, Inc. and related entities initially reported holding 1,116,421 voting rights (3.25%) on October 8, 2024, crossing the 3% threshold.
• However, BlackRock's holdings subsequently fell to 2.99% (1,116,421 voting rights) on October 9, 2024, due to a passive downward crossing of the 3% threshold.

These notifications were made in accordance with Belgian transparency regulations for large shareholdings.

Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) has released an update on its total number of voting rights and shares as of October 9, 2024. This disclosure is in compliance with article 15 of the Law of 2 May 2007 on the disclosure of large shareholdings. The key details are:

Share capital: EUR 6,423,111.21
Total securities with voting rights: 37,389,015 (all ordinary shares)
Total voting rights (denominator): 37,389,015
Unissued securities with voting rights: 2,039,481 granted subscription rights (excluding 643,394 issued but not granted)

Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) received a transparency notification from BlackRock, Inc. on October 7, 2024, following changes in BlackRock's group structure. The notification, dated October 3, 2024, indicates that BlackRock, Inc. and its controlled undertakings now hold 1,116,421 voting rights, representing 3.25% of the total voting rights (34,389,015) as of October 1, 2024.

The holdings consist of 1,032,521 shares and 83,900 equivalent financial instruments. This change resulted from the acquisition of Global Infrastructure Partners, which led to a restructuring of BlackRock's group. The notification details the full chain of controlled undertakings and provides a breakdown of voting rights held by various BlackRock entities.

Nyxoah SA (NYXH) has successfully raised $27 million through its at-the-market (ATM) offering, selling 3 million shares to a single U.S.-based healthcare investor. The shares were sold at market price on the Nasdaq Global Market, with Cantor Fitzgerald & Co. acting as the sales agent. This transaction was conducted under Nyxoah's $50 million ATM program and its shelf registration statement on Form F-3.

CEO Olivier Taelman emphasized that this investment reinforces Nyxoah's U.S. focus and strengthens its financial position as the company prepares for the launch of Genio® in the United States. The funding follows the presentation of compelling DREAM pivotal study data at the International Surgical Sleep Society (ISSS) congress and aligns with Taelman's recent relocation to the U.S.

Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) has released information on its total number of voting rights and shares as of September 27, 2024, in compliance with Belgian law. The company's share capital stands at EUR 5,907,711.21, with a total of 34,389,015 securities carrying voting rights, all of which are ordinary shares. The total number of voting rights is also 34,389,015.

Additionally, Nyxoah reports 2,040,231 rights to subscribe to securities carrying voting rights not yet issued. This figure excludes 643,394 subscription rights that have been issued but not yet granted. The disclosure is part of the company's regulatory obligations regarding the transparency of large shareholdings.

Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) received a transparency notification from BlackRock, Inc. on September 24, 2024. The notification indicates that BlackRock Advisors, went below the 3% threshold on September 20, 2024. As of that date, BlackRock, Inc. and its controlled undertakings held 1,116,421 voting rights, representing 3.25% of the total voting rights (34,373,015).

The notification details include:

• 1,043,221 shares and 73,200 equivalent financial instruments
• BlackRock Advisors, holding 2.96% of voting rights
• BlackRock Fund Advisors, BlackRock Investment Management (UK) , and BlackRock Investment Management, holding smaller percentages

The full chain of controlled undertakings and additional information about the disclosure obligation are provided in the press release.

Nyxoah SA (NYXH), a medical technology company focused on innovative solutions for Obstructive Sleep Apnea (OSA), has announced its participation in three upcoming investor conferences in New York City. The company's CEO, Olivier Taelman, will deliver corporate updates at:

• Baird Global Healthcare Conference on September 10, 2024, at 12:15pm ET
• H.C. Wainwright 26th Annual Global Investment Conference on September 11, 2024, at 11:00am ET
• Cantor Global Healthcare Conference on September 18, 2024, at 1:55pm ET

Webcasts of the presentations will be available on Nyxoah's Investor Relations website. The company will also be available for one-on-one meetings with institutional investors attending these events.

Nyxoah SA (NYXH) celebrated its progress towards U.S. market entry by ringing the Nasdaq Closing Bell on August 29, 2024. The company, focused on innovative solutions for Obstructive Sleep Apnea (OSA), has completed its FDA regulatory submission for the Genio® device. Nyxoah is on track for U.S. approval by the end of 2024 and plans a commercial launch in early 2025.

Key highlights include:

• Positive data from the pivotal DREAM study in spring 2024
• Final module submitted for FDA review
• U.S. commercial team established, led by new CCO Scott Holstine
• Over €85 million raised to fund U.S. launch

Nyxoah SA (NYXH) reported its Q2 and H1 2024 financial results. Key highlights include:

• Completed FDA regulatory submission, with U.S. approval expected by end of 2024
• Raised over €85 million in growth capital
• Q2 2024 sales of €0.8 million
• H1 2024 sales growth of 29% year-over-year
• Total cash position of €77.8 million at quarter-end

The company is focusing on U.S. commercial readiness, with key leadership appointments made. Nyxoah's cash runway extends into mid-2026, fully funding the U.S. launch. Q2 operating loss was €13.3 million, driven by increased R&D spending and ongoing commercial and clinical activities.